GlassScriptPhysician profile
Said Ibrahimi
NPI 1376751321
$17,484.85
in general payments reported to CMS, 2019-2025
63 companies · $3,105 in 2025
The $3,105 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $912 · 2021: $2,686 · 2022: $2,975 · 2023: $3,920 · 2024: $3,183 · 2025: $3,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $18.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,190.56 |
| Education | $18.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,547.02 | 2019-2025 | |
| Ucb, INC. | $1,475.60 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Lilly USA, LLC | $1,393.56 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Teva Pharmaceuticals USA, INC. | $1,083.29 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biogen, INC. | $962.66 | 2019-2024 | Vumerity, Tysabri, Plegridy |
| Neurocrine Biosciences, INC. | $820.92 | 2024-2025 | Ingrezza |
| Sk Life Science, INC. | $795.35 | 2021-2024 | Xcopri |
| Pfizer INC. | $765.10 | 2023-2025 | |
| Acorda Therapeutics, INC | $753.10 | 2022-2024 | Inbrija, Ampyra |
| Sumitomo Pharma America, INC. | $688.46 | 2023-2024 | Aptiom |
| Neurelis, INC. | $649.91 | 2022-2025 | Valtoco |
| Sunovion Pharmaceuticals INC. | $610.42 | 2021-2022 | |
| Allergan, INC. | $511.87 | 2019-2021 | |
| Eisai INC. | $507.85 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $413.38 | 2019-2025 | Nuedexta, Rexulti |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Said Ibrahimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.